Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers August 5, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - August 5, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

8/5/15 - Shire pharmaceutical makes $30bn move for Baxalta
The London- listed drug company Shire has made a $30 bn hostile takeover bid for the rare-disease specialist Baxalta. Shire announced it was ready to pay $45.23 per Baxalta share, a 36% premium on Baxalta s stock price on Monday. Shire s play for Baxalta comes after it was nearly taken over itself by Illinois- based rival AbbVie in 2014. The
8/5/15 - Supernus Announces Second Quarter 2015 Financial Results
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today reported financial results for the second quarter of 2015 and associated company developments. "Strong growth in product prescriptions in the quarter reflects the solid.
8/4/15 - 22ND CENTURY GROUP, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Some of the factors that could cause actual results to differ include: our ability to continue to monetize the licensing of our technology and products; our ability to raise capital; our ability to achieve profitability; our ability to manage our growth effectively; our ability to obtain FDA clearance for our Modified Risk Cigarettes; our ability t
8/4/15 - ABLYNX INITIATES PHASE II SLE STUDY WITH ITS ANTI-IL-6R NANOBODY, PARTNERED WITH ABBVIE
Phase II study to evaluate the efficacy and safety of ALX-0061, administered subcutaneously, in patients with moderate to severe, active systemic lupus erythematosus GHENT, Belgium, 4 August 2015- Ablynx today announced that it has administered the first dose in the Phase II STEADY study to evaluate the efficacy and safety of its anti-IL-6R Nanobod
8/4/15 - Access Carroll receives grant for pharmacy program [Carroll County Times, Westminster, Md.]
Aug. 04 Access Carroll recently received a $25,000 from the Quality Health Foundation to support a pharmacy program, regarded in the health care field as pioneering, that helps ensure clients are able to secure the medications they need free of charge through pharmaceutical company financial assistance programs. It's the latest in series of such
8/4/15 - ACELRX PHARMACEUTICALS INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Examples of these statements include, but are not limited to, statements regarding: the process and timing of anticipated future development of AcelRx's product candidates, including Zalviso and ARX-04, including the upcoming General Advice meeting with the U.S. Food and Drug Administration, or FDA, for Zalviso scheduled in early September 2015; Ac
8/4/15 - Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir and Odalasvir (ACH-3102) on AL-335... [tayyar.org (Lebanon)]
-Achillion Pharmaceuticals, Inc. announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir on the pharmacokinetics of AL-335 in healthy volunteers. As previously announced on May 19, 2015, Achillion has granted Janssen a
8/4/15 - Akorn Appoints Randy Pollard as Interim Chief Financial Officer
Akorn, Inc. today announced the appointment of Randall Pollard as Chief Accounting Officer and Interim Chief Financial Officer. Mr. Pollard joined Akorn as Vice President and Corporate Controller in April 2015 from Novartis Pharmaceuticals, where he served as the head of accounting and reporting for Novartis' generic division, Sandoz.
8/4/15 - Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company focused on developing and commercializing innovative, non-systemic, oral protein therapeutics to treat metabolic and orphan diseases, today announced that the first patient has been treated in its Phase 2 b dose-ranging study of ALLN-177, an orally administered recombinant...
8/4/15 - Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 12, 2015
Amphastar Pharmaceuticals, Inc. announced that the Company will release results for its second quarter of 2015 ended June 30, 2015, after the market closes on Wednesday, August 12, 2015, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time. This press release contains forward-looking statements, including sta
8/4/15 - AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT
Shares of Common Stock Will Begin Trading on a Split-Adjusted Basis on August 07, 2015. SAN DIEGO& RICHMOND, Va.& LJUBLJANA, Slovenia& SYDNEY AmpliPhi BioSciences Corporation, a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a..
8/4/15 - ANI PHARMACEUTICALS INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many important factors, including those set forth under "Risk Factors" in our annual report on Form 10- K for the year ended December 31, 2014. EXECUTIVE OVERVIEW ANI Pharmaceuticals, Inc. and its wholly-owned, consolidated subsidiary,
8/4/15 - Ascendis Health expands to Spain with acquisition [Bizcommunity (South Africa)]
Ascendis Health has made its first international acquisition with the purchase of a 49% stake in Spanish pharmaceutical group, Farmalider for R210 million... The Madrid- based company develops and manufactures mainly generic pharmaceutical products, with a market leading position in the ibuprofen and paracetamol markets in Spain. CEO, Dr Karsten We
8/4/15 - Bausch + Lomb's VICTUS Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Enhanced Patient Interface Kit
Release date- 03082015- BRIDGEWATER, NJ- Bausch+ Lomb, a leading global eye health company, announced today its VICTUS Femtosecond Laser Platform has received 510 clearance from the U.S. Food and Drug Administration for an enhanced patient interface kit. The interface features a smaller diameter suction clip, which has been modified to allow for ea
8/4/15 - Biotech Sector Review
Focus on 4 Emerging Biotech Companies. NEW YORK, NY/ ACCESSWIRE/ August 4, 2015/ Recently, the four tickers Immunomedics Inc., KaloBios Pharmaceuticals Inc., Pluristem Therapeutics Inc., and Arrowhead Research Corp have been attracting investors' attention. Nonetheless, recent years have seen some positive news in relation to FDA approvals and U.S.
8/4/15 - Capricor Therapeutics Appoints Deborah Ascheim, M.D. as Chief Medical Officer
Capricor Therapeutics, Inc., a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics, today announced the appointment of Deborah D. Ascheim, M.D., to the position of Chief Medical Officer. Prior to her tenure at Mount Sinai, Dr. Ascheim was on faculty in the Department of Medicine and div
8/4/15 - Catabasis Pharmaceuticals to Present at the Wedbush PacGrow Healthcare Conference
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present a company overview at the Wedbush PacGrow Healthcare Conference. The Wedbush PacGrow Healthcare Conference will be held August 11- 12, 2015, in New York, NY at Le Parker Meridien
8/4/15 - Catalyst Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Tuesday, August 11th, 2015
Catalyst Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today announced that it will release Second Quarter financial results after market close on Monday, August 10, 2015. Catalyst management will host an investment-community conference call.
8/4/15 - Celator Pharmaceuticals to Report Second Quarter 2015 Financial Results on August 11, 2015
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Tuesday, August 11, 2015 at 4:30 p.m. ET to report second quarter 2015 financial results.
8/4/15 - Cempra to Present at the Wedbush PacGrow 2015 Healthcare Conference
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced it will be participating in the Wedbush PacGrow 2015 Healthcare Conference. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra, is sche
8/4/15 - Change of Guard at the Helm - Report on Juniper Pharmaceuticals, Inc.
ACI Association has initiated research coverage on Juniper Pharmaceuticals, Inc.. Appointment of New Chairman- On July 16, 2015, Juniper Pharmaceuticals, Inc. announced several changes to its Board of Directors. The specialty pharmaceutical company focused on developing women-related therapeutics informed that James A. Geraghty has been appointed a
8/4/15 - Ciclofilin Pharmaceuticals Receives Notice of Patent Allowance for Novel Cyclophilin Inhibitor
Ciclofilin Pharmaceuticals Inc., a privately held biotech, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/ 994,707 entitled, "Cyclosporine Analogue Molecules Modified at Amino Acid 1 and 3." This Intellectual Property expands the Company's portfolio of...
8/4/15 - Codexis Announces CodeEvolver Technology Transfer and License Agreement With Merck [Emirates News Agency (WAM) (United Arab Emirates)]
-Codexis, Inc., a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces the signing of a CodeEvolver platform technology license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. This transaction marks the second CodeEvolver licensing agreement between Codexi
8/4/15 - Cumberland Pharmaceuticals Reports Second Quarter & Year To Date 2015 Financial Results
As of June 30, 2015 the Company had approximately $93 million in total assets including $53 million in cash and investments. Cumberland also had nearly $44 million in tax net operating loss carryforwards, resulting from the prior exercise of stock options. Progressing with the Caldolor supplemental New Drug Application requesting a label update
8/4/15 - CytRx Reports 2015 Second Quarter Financial Results [Global Data Point]
"The second quarter of 2015 has been very productive for CytRx. Enrollment in our ongoing pivotal global Phase 3 clinical trial of aldoxorubicin in soft tissue sarcoma continues on track to be completed in the first quarter of 2016. On the financial front, we successfully closed a public equity offering raising an additional $28.8 million in gross
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415